A better comprehension of the aberrant epigenetic events occurring in LAM/TSC cells may be useful in the development of more effective therapeutic interventions also based on chromatin-remodelling agents aimed at the epigenetic silencing relief of the TSC2 [16,45]. The gene discussed is TSC1; the disease is lymphangioleiomyomatosis.